抗凝的景观发生了变化:重点是直接口服抗凝剂
Walter Ageno1, Bruno Caramelli2, Marco Paolo Donadini3
1Department of Internal Medicine, Ospedale Regionale di Bellinzona e Valli, Bellinzona, Switzerland; Department of Medicine and Surgery, University of Insubria, Varese, Italy.
The Lancet. Haematology
|October 21, 2024
概括
直接口服抗凝剂 (DOAC) 已经改变了抗凝作用,成为许多疾病的标准. 然而,DOACs并非对所有患者都有效,在特定的临床场景中需要仔细考虑.
科学领域:
- 心脏病学 心脏病学
- 血液学 血液学 血液学
- 药理学 药理学 是一个学科.
背景情况:
- 从2010年代初开始,直接口服抗凝剂 (DOAC) 彻底改变了抗凝疗法.
- 现在,DOAC已被广泛用于预防中风,治疗心房动和静脉血栓栓塞.
- 大约三分之二的需要口服抗凝药的患者现在使用DOACs.
研究的目的:
- 审查过去十年中DOACs在临床实践中的影响.
- 探索DOACs的新兴应用和正在进行的研究领域.
- 讨论在管理DOAC治疗中的实际挑战和考虑.
主要方法:
- 营销后研究和第三阶段临床试验数据的审查.
- 对多种不同患者群体的DOAC疗效和安全性的分析.
- 综合当前的临床实践指南和专家建议.
主要成果:
- DOAC已在诸如外周动脉疾病,癌症相关血栓形成和末期脏疾病等疾病中表现出有效性.
- 在患有膜心房动,机械心脏门和抗脂综合征的患者中,DOAC被发现是无效的.
- 市场发布后的数据在很大程度上证实了第三阶段试验的结果,正在进行的研究正在探索新的迹象.
结论:
- DOACs代表了抗凝固药的重大进步,在广泛的患者群体中提供了好处.
- 仔细选择患者至关重要,因为DOACs不是普遍有效的,并且有禁忌.
- 持续的研究和实际的管理策略对于优化DOAC治疗至关重要.
更多相关视频
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
625
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
625
Venous Thrombosis III: Interprofessional Care
2
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
2
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
478
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
478
Venous Thrombosis IV: Nursing Management
2
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
2
Antihypertensive Drugs: Direct Renin Inhibitors
499
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
499


